Published online before print May 15, 2003, doi: 10.1161/01.STR.0000072983.64326.53
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:1539.)
© 2003 American Heart Association, Inc.
Comments, Opinions, and Reviews |
Recommendations for Advancing Development of Acute Stroke Therapies
Stroke Therapy Academic Industry Roundtable 3
From the Department of Neurology, University of Massachusetts/Memorial Healthcare, Worcester, Mass.
Reprint requests to Marc Fisher, MD, Department of Neurology, UMASS/Memorial Healthcare, 119 Belmont St, Worcester, MA 01605. E-mail fisherm{at}ummhc.org
Background— The development of acute stroke therapy has proven to be a daunting task, with a few successful and many unsuccessful trials. New strategies need to be considered to enhance the chances for success in future trials.
Summary of Review— The third Stroke Therapy Academic Industry Roundtable (STAIR) conference focused on issues related to increasing the percentage of acute stroke patients who might be included in acute stroke therapy trials and ultimately treated with drugs proven to be effective. A second focus was directed at the need for implementing multimodality stroke trials and potential ways to organize such trials in the near future. Finally, concepts for organizing and implementing acute stroke trials that incorporate current, state of the art trial methodology were discussed.
Conclusions— It is hoped that these suggestions will enhance future stroke trials and the development of effective, new acute stroke treatments that are maximally effective and utilized.
Key Words: clinical trials • drug therapy, combination • patient selection • stroke management
This article has been cited by other articles:
 |
|
 |
|
  H.-C. Diener, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, A. Shuaib, T. Ashwood, W. Wasiewski, V. Alderfer, et al. NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials Stroke, June 1, 2008; 39(6): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan The 2007 Feinberg Lecture: A New Road Map for Neuroprotection Stroke, January 1, 2008; 39(1): 242 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shuaib, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, H.-C. Diener, T. Ashwood, W. W. Wasiewski, U. Emeribe, et al. NXY-059 for the Treatment of Acute Ischemic Stroke N. Engl. J. Med., August 9, 2007; 357(6): 562 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver Clinical Impact of NXY-059 Demonstrated in the SAINT I Trial: Derivation of Number Needed to Treat for Benefit Over Entire Range of Functional Disability Stroke, May 1, 2007; 38(5): 1515 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Goldberg New Approaches to Clinical Trials in Neuroprotection: Introduction Stroke, February 1, 2007; 38(2): 789 - 790. [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher, D. F. Hanley, G. Howard, E. C. Jauch, S. Warach, and for the STAIR Group Recommendations From the STAIR V Meeting on Acute Stroke Trials, Technology and Outcomes Stroke, February 1, 2007; 38(2): 245 - 248. [Full Text] [PDF]
|
|
|
|
|
|
MR Stroke Collaborative Group Proof-of-Principle Phase II MRI Studies in Stroke: Sample Size Estimates From Dichotomous and Continuous Data Stroke, October 1, 2006; 37(10): 2521 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Wu, S. Christensen, N. Hjort, R. M. Dijkhuizen, T. Kucinski, J. Fiehler, G. Thomalla, J. Rother, and L. Ostergaard Characterizing physiological heterogeneity of infarction risk in acute human ischaemic stroke using MRI Brain, September 1, 2006; 129(9): 2384 - 2393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-S. Loh, K. S. Butcher, M. W. Parsons, L. MacGregor, P. M. Desmond, B. M. Tress, and S. M. Davis Apparent Diffusion Coefficient Thresholds Do Not Predict the Response to Acute Stroke Thrombolysis Stroke, December 1, 2005; 36(12): 2626 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Molina and J. L. Saver Extending Reperfusion Therapy for Acute Ischemic Stroke: Emerging Pharmacological, Mechanical, and Imaging Strategies Stroke, October 1, 2005; 36(10): 2311 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher and for the Stroke Therapy Academic Industry Roundtabl Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable Stroke, August 1, 2005; 36(8): 1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan, S. M. Davis, and J. Ludbrook The Bayesian Principle: Can We Adapt? Stroke, July 1, 2005; 36(7): 1623 - 1624. [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lutsep Current Status of Hemorrhagic Stroke and Acute Nonthrombolytic Ischemic Stroke Treatment Stroke, November 1, 2004; 35(11_suppl_1): 2746 - 2747. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver, C. Kidwell, M. Eckstein, S. Starkman, and for the FAST-MAG Pilot Trial Investigators Prehospital Neuroprotective Therapy for Acute Stroke: Results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Pilot Trial Stroke, May 1, 2004; 35(5): e106 - e108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome Stroke, May 1, 2004; 35(5): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Williams, R. Berti, J. R. Dave, P. J. Elliot, J. Adams, and F. C. Tortella Delayed Treatment of Ischemia/Reperfusion Brain Injury: Extended Therapeutic Window with the Proteosome Inhibitor MLN519 Stroke, May 1, 2004; 35(5): 1186 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Macleod, T. O'Collins, D. W. Howells, and G. A. Donnan Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias Stroke, May 1, 2004; 35(5): 1203 - 1208. [Abstract] [Full Text] [PDF]
|
|